Nowoczesne metody diagnostyki kardiotoksycznosci antracyklin u pacjentow z chloniakami


Author(s): Beata Kumiega, Andrzej Pluta, Jacek Krzanowski

Anthracyclines, show a strong antitumour activity in the treatment of solid and haematological malignancies. They may be responsible for cardiac side effects. Initially, cardiac damage induced by anthracyclines is subclinical, however increasingly impaired cardiac function can result chronic heart failure. The assessment of the myocardial damage, especially at its initial stage is very important however difficult. There is a continuous need for new methods introduction of early detection of cardiac damage.

Share this article

Editors List

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)

  • Skowronska-Gardas

    Department of Radiotherapy, Oncology Center-Institute (Warsaw, Poland)

  • Serban-Dan Costa

    Head of the Obstetrics and Gynecology Clinic of the University of Otto von Guericke (Magdeburg, Germany)